Skip to main content

Leveraging Automation in Pharma Regulatory

 Over the past decade, technology has played a pioneering role in driving biopharmaceutical innovation and created significant disruption in the regulatory environment. 

The regulatory aspects of Chemistry, Manufacturing, and Control (CMC) are evolving rapidly with advancements such as analytics, automation, robotics, and blockchain, becoming mainstream in strategic and operational functions.

Automated Regulatory Equals Scrutinized Compliance

One of the many revolutionizing technologies – intelligent automation – has now become an inseparable part of several business functions. 

From lowering costs to simplifying data gathering between different systems, automation presents numerous opportunities to enhance quality and efficiency. Technologies in artificial intelligence (AI) such as machine learning (ML) and natural language processing (NLP) take over manual, repetitive, and time-consuming tasks to achieve self-evolving, automated systems with rapid outcomes. 

Let us take a look at a couple of scenarios where technology could potentially disrupt the traditional regulatory process.

  • Handling Data Silos

Due to the prevailing non-interoperable legacy enterprise systems, regulatory teams across the world, face issues such as inconsistent and incomplete data filing. 

It is cumbersome to ascertain if the organization is using the latest documentation process, especially when users across the globe are using disparate systems, leading to inconsistent filings and submission errors. 

This is where the power of automation and AI can be leveraged effectively, to conceptualize and create an intelligent web-based system with access to all artifacts. This web-based system accounts for a ‘single source of truth’ that can provide consistent and complete data through a central repository for all types of documents.

 Further, automated processing and AI improves customer service, increases productivity, helps groups meet compliance requirements, and lowers costs.

  • Automating Regulatory CMC data

With the traditional regulatory approach, it is difficult to collate, process, analyze, archive, and exchange data effectively and ensure cost efficiency. This can result in delayed submissions leading to late approvals for drugs. 

If regulatory CMC data is not managed effectively, pharmaceutical companies become vulnerable to the risk of non-compliance, which when coupled with issues in data integrity, can lead to application rejection and degradation of the organization’s reputation. 

In order to overcome these challenges, pharmaceutical companies need to analyze the existing regulatory process workflows, identify operational and technological gaps, and adopt automation techniques. 

A centralized repository with automated responses to health authority (HA) questions coupled with AI-driven extraction engine for reading and interpreting HA query responses is a good example of automation in this scenario.

 Every time a new HA query enters the system, the AI-enabled smart search engine will be able to search the internal repository for the right response to questions with the help of reference data. 

This also enables the re-use of data, brings speed to response authoring and compilation, and reduces overall cycle time for faster approvals.

Effective Regulatory Automation

Irrespective of the fact that technology can benefit pharmaceutical companies, regulatory CMC and operations teams need to assess the real need for automation and the ways it can improve process efficiencies. To begin with, specific process automation requirements can be defined by:

 1. Mapping the entire end-to-end processes

 2. Identifying process steps that can be automated

 3. Leveraging appropriate criteria to understand the logic for automation, maturity of process and business value, and availability of data

The target model for automation can be defined with the help of the aforementioned steps following the evaluation process. For effective management of regulatory automation, organizations must pay attention to the following aspects:

  • Intelligent operations: Pushes data-driven models through smart alerts and workflows.

  • Technology simplification: Enables programs focused on process automation and rationalization, and makes the technology landscape smarter, scalable, and future ready.

  • Data repositories: Implement databases and invest in development capabilities in advanced analytics. Improve data quality and accuracy by adopting standard approaches and allied technologies.

  • AI and cognitive: Leveraging AI technologies to convert information from structured and unstructured sources into knowledge and actionable insights.

The Way Forward

Considering the limited scope for change in regulatory procedures, the pharmaceutical industry needs to focus on automating the approaches that can propel business momentum without impacting the desired outcome. 

While automation will result in significant time savings for regulatory development and compliance teams, it also ensures better data reliability. Furthermore, it allows the possibility of analyzing data in more meaningful ways by connecting different data sources and conducting data crosschecks.

It is evident that regulatory process automation will spur the current process and act as a catalyst for the existing tools in obtaining desired outcomes, accelerating regulatory submissions, and expediting product approval processes.

Comments

Post a Comment

Popular posts from this blog

Social Responsibililty

                                                                        SOCIAL RESPONSIBILITY Social Responsiblity   is an ethical framework and suggests that an entity, be it an organization or individual, has an obligation to act for the benefit of society at large.  Social responsibility  is a duty every individual has to perform so as to maintain a balance between the economy and the ecosystems.  4 Types of Social Responsibility Corporate Environmental Responsibility. ... Corporate Human Rights Responsibility. ... Corporate Philanthropic Responsibility. ... Corporate Economic Responsibility. Some of the common Responsibility for example given below: Reducing carbon footprints. Improving labor policies. Participating in fair trade. Charitable givin...

Online Education

ONLINE EDUCATION Online education is a flexible instructional delivery system that encompasses any kind of learning that takes place via the  Internet . Online learning gives educators an opportunity to reach students who may not be able to enroll in a traditional classroom course and supports students who need to work on their own schedule and at their own pace. The quantity of distance learning and online degrees in most disciplines is large and increasing rapidly. Schools and institutions that offer online learning are also increasing in number. Students pursuing degrees via the online approach must be selective to ensure that their coursework is done through a respected and credentialed institution. POSITIVE AND NEGATIVE EFFECTS OF LEARNING ONLINE Online education offers many positive benefits since students: have flexibility in taking classes and working at their own pace and time face no commuting or parking hassles learn to become responsible for their own education with in...

COVID-19 Drives Insurers to Revisit Actuarial Models

The COVID-19 pandemic has taken a huge toll on people and economies alike.  Governments and central banks worldwide have introduced a slew of fiscal measures to infuse liquidity and stability in the market.  However, in spite of these measures, the financial markets are expected to remain highly volatile for a significant duration, likely to worsen further due to lowering of interest rates and increasing credit spread gaps as well as risk of mortgage defaults.  Insurers therefore need to assess the impact on their solvency margins and IRRs, and re-assess the assumptions around mortality and morbidity rates, operational and financial costs, claims and losses, and so on.   Actuaries must review existing strategies and products and construct new ones to handle evolving risks and their interactions to be able to better model assets and liabilities as well as analyze asset and capital adequacies Moreover, insurers will have to perform strong scenario testing to identify k...